Status:

COMPLETED

Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas

Lead Sponsor:

Hellenic Oncology Research Group

Collaborating Sponsors:

University Hospital of Crete

Conditions:

Ovarian Cancer

Eligibility:

FEMALE

18-75 years

Phase:

PHASE1

PHASE2

Brief Summary

This trial will determine the feasibility and toxicity of dose intense (every 2 weeks) of paclitaxel+carboplatin combination following cytoreductive surgery in patients with stage Ic-IV ovarian cancer...

Detailed Description

Dose dense chemotherapy has been proven beneficial in various oncological settings. It is proposed that this concept be tested in ovarian cancer, with the support of growth factors. It is hypothesized...

Eligibility Criteria

Inclusion

  • Histologically- or cytologically- confirmed ovarian cancer requiring standard chemotherapy
  • Patients have to be chemotherapy naive
  • Patients may have undergone cytoreductive surgery, or this may have been omitted due to dissemination
  • Age \>18 years.
  • Performance status (WHO) 0-2
  • Life expectancy of at least three months.
  • Adequate bone marrow function (Absolute neutrophil count \>1000/mm\^3, Platelet count\>100000/mm\^3, Hemoglobin\>9gr/mm\^3).
  • Adequate liver (Bilirubin\<1.5 times upper limit of normal and SGOT/SGPT\<2 times upper limit of normal) and renal function (creatinine\<2mg/dl)
  • Informed consent

Exclusion

  • Pregnant or nursing
  • Psychiatric illness or social situation that would preclude study compliance'
  • Other concurrent uncontrolled illness
  • No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

Key Trial Info

Start Date :

January 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2011

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT00750386

Start Date

January 1 2008

End Date

March 1 2011

Last Update

May 23 2011

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

University Hospital of Crete

Heraklion, Crete, Greece, 71110

2

University General Hospital of Alexandroupolis, Dep of Medical Oncology

Alexandroupoli, Greece

3

"IASO" General Hospital of Athnes, Dep of Medical Oncology

Athens, Greece

4

"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine

Athens, Greece